Skip to content
Hair Pipeline
← Back to the pipeline

VC005

An undisclosed oral Vcare candidate at phase 2, in two registered trials.

Phase 2OralUndisclosed
Developed by
Jiangsu Vcare Pharmaceutical
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Indications
Androgenetic alopecia
Also known as
VC005 tablets
Last public activity
August 2026
Record confidence
Low

Why it matters

An oral tablet rather than another topical, which is the harder regulatory path and implies the sponsor thinks it needs systemic exposure. Two trials registered; composition undisclosed.

Development history

  1. Phase 2

    First Phase 2 trial on record: NCT07749716 — Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT07762443Phase 1NOT YET RECRUITING

    A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata

    Jiangsu vcare pharmaceutical technology co., LTD · n=24 · September 2026

  • NCT07749716Phase 2NOT YET RECRUITING

    Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

    Jiangsu vcare pharmaceutical technology co., LTD · n=120 · August 2026

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources